Australia's most trusted
source of pharma news
Monday, 20 May 2024
Posted 21 April 2023 AM
Roche's $20 million investment in Omico's genomics testing program aimed at getting targeted cancer treatments to Aussie patients quicker appears to be paying off with the not-for-profit organisation now calling for other pharma's to join the cause.
The Swiss pharma is among four core partners of Omico's Project PrOSPeCT, which received $185 million in funding early in 2022, including over $61 million from the government.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.